Patient expectations and experiences of multiple sclerosis interferon β-1a treatment: A longitudinal, observational study in routine UK clinical practice

Patient Preference and Adherence

Volumn 8, Issue , 2014, Pages 247-255

  Syed, Mehmood ^a   Rog, David ^b   Parkes, Laura ^c   Shepherd, Gillian L ^c  

^a Bupa Home Healthcare   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c Merck Serono Ltd   (United Kingdom)

Author keywords

Adherence; Drug delivery; Interferon 1a; Multiple sclerosis; Persistence

Indexed keywords

EID: 84894271130     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S46421     Document Type: Article

References (22)

1. Bennett JL, Stüve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol. 2009;32(3):121-132.
2. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61-76.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46(4):907-911.
4. Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2009;10(2):291-309.
5. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003. Available from: http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf. Accessed March 22, 2013.
6. Río J, Porcel J, Téllez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11(3):306-309.
7. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11(1):46-50.
8. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006;38(3): 167-171.
9. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28(1):51-61.
10. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6(9):995-1002.
11. Rebif Summary of Product Characteristics [webpage on the Internet]. UK: Datapharm Communications, Ltd; 2013. Available from http://www.medicines.org.uk/EMC/medicine/22392/SPC/Rebif solution for injection in pre-filled syringes/. Accessed March 22, 2013.
12. Heeren T, D'Agostino R. Robustness of the two independent samples t-test when applied to ordinal scaled data. Stat Med. 1987;6(1): 79-90.
13. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61(4):551-554.
14. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.
15. http://www.abpi.org.uk/Pages/default.aspx [homepage on the Internet]. Association of the British Pharmaceutical Industry. Demonstrating Value with Real World Data. 2011. The Association of the British Pharmaceutical Industry; 2011. Available from: http://www.abpi.org.uk/our-work/library/guidelines/Pages/real-world-data.aspx. Accessed March 22, 2013.
16. Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997;314(7094):1580-1583.
17. Riñon A, Buch M, Holley D, Verdun E. The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence. 2011;5:629-643.
18. Exell S, Verdun E, Driebergen R. A new electronic device for subcutaneous injection of IFN-β-1a. Expert Rev Med Devices. 2011;8(5): 543-553.
19. Giovannoni G, Barbarash O, Casset-Semanaz F, et al; Rebif New Formulation Study Group. Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler. 2009;15:219-228.
20. Beer K, Müller M, Hew-Winzeler AM, et al. The prevalence of injectionsite reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol. 2011;11:144.
21. Mesaroš S, Stojsavljeví N, Dujmoví-Bašuroski I, Dejanović I, Pekmezoví T, Drulović J. Long-term adherence to interferon-beta treatment in a cohort of RRMS patients in Belgrade, Serbia. Clin Neurol Neurosurg. 2012;114(8):1145-1148.
22. Vicente Iturbe C, Ara Callizo JR, Huarte Lacunza R, Navarro Aznárez H, Serrano Mislata N, Rabanaque Hernández MJ. [Discontinuation and long-term adherence to beta interferon therapy in patients with multiple sclerosis]. Farm Hosp. 2012;36(2):77-83. Spanish.